Newswise — ATLANTA — New research findings presented at the 2019 ACR/ARP Annual Meeting found that annual spending on biologic DMARDS (biologics) by U.S. public programs and beneficiaries nearly doubled from 2012 to 2016. The study showed post-market drug price changes alone account for the majority of recent spending growth, and manufacturers’ rebates have little impact on rising costs (Abstract #2731).
Biologics are genetically engineered proteins made from human genes that are designed to reduce inflammation and stop disease progression by targeting inflammation-causing agents in the body. While effective, biologics can be costly.
The American public spends billions of dollars each year on biologics, but it is still unclear what factors are driving recent increases in spending and per-patient costs for these drugs. This statistical cost analysis characterized changes in total spending and unit prices for biologics in Medicare and Medicaid and quantified the major sources of spending increases on biologics for public programs and their beneficiaries. Rising drug costs were the main reason for the new study.
“The potential drivers of biologic spending increases have different implications for patient and taxpayer expenditures, and ways to control costs,” says Natalie McCormick, PhD, post-doctoral fellow at Massachusetts General Hospital and Harvard Medical School, and the study’s lead author. “If more patients are receiving biologics, total spending may increase, but the average costs for each patient may not. In contrast, price increases can have a considerable impact on patients’ out-of-pocket costs, as biologics are in specialty tiers where patients pay a percentage of the list price, not a copayment. This can have financial and clinical consequences, as high out-of-pocket costs have posed barriers to biologic initiation and adherence.”
The researchers accessed Medicare Parts B and D and Medicaid drug spending data from 2012 to 2016. These data contained aggregated prescription claims for all beneficiaries enrolled in Medicare Part B (fee for service) and Part D (stand-alone or Medicare Advantage Plans), or Medicaid. All biologics approved by the U.S. Food and Drug Administration (FDA) for one or more rheumatic diseases through December 2014 were included in the study. For each biologic and calendar year, the researchers extracted total annual spending, and number of recipients, claims and doses dispensed, and then calculated the drug unit price or average cost per dose.
For the statistical analysis, they calculated five-year changes in total spending and unit prices for each biologic and in-aggregate, after adjusting for general inflation to 2016 dollars. Then, they isolated the contributions of four sources of spending growth: drug prices, number of recipients (or uptake), treatment intensity (the mean number of doses per claim) and the annual number of claims per recipient for each biologic. They conducted their analysis by including statutory Medicaid rebates, as these decrease public spending, and both excluding and including Medicare rebates, as these are paid by drug manufacturers to pharmacy benefit managers (PBMs) and Part D plans, but do not directly impact patient or taxpayer spending. They used time-varying rebates reported by the Congressional Budget Office.
The study’s results showed that from 2012 to 2016, annual spending by U.S. public programs and beneficiaries nearly doubled from $5.3 billion to $10.3 billion for the 11 biologics included in the study. Drug prices increased by a mean of 52 percent in Medicare Part D and 20 percent in Part B. Controlling for general inflation, unit price increases alone accounted for 56 percent or $1.7 billion of the five-year, $3.0 billion spending increase within Part D. Increased uptake accounted for 37 percent or $1.1 billion. After they accounted for time-varying rebates, price hikes for these drugs were still responsible for 53 percent or $1.4 billion of the Part D spending increase.
Adalimumab and etanercept, two of the oldest biologics, were prescribed to the largest numbers of Part D beneficiaries and also had the biggest unit price increases. Medicaid spending and price trends were similar to Part D. The majority of spending growth for the oldest Part B drugs--rituximab, abatacept and infliximab--was due to price increases, while increases in the number of recipients was the main driver of spending growth for the five newer drugs—golimumab, ustekinumab, tocilizumab, certolizumab and belimumab.
“With prices increasing, our findings underlie the importance of rheumatologists and patients discussing the costs of DMARD treatment and options for mitigating cost concerns and barriers to effective treatment. These will differ depending on each patient’s financial circumstances and extent of their Medicare coverage, says Dr. McCormick. “We did not have access to individual-level data in this study but would like to investigate how price increases may impact patients’ out-of-pocket costs and adherence to therapy over the long term, and which diagnoses had the biggest increases in biologic uptake. It will also be interesting to assess the impact of biosimilars on public spending.”
This research was supported by funding from the Canadian Institutes of Health Research, Rheumatology Research Foundation and the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases.
About the ACR/ARP Annual Meeting
The ACR/ARP Annual Meeting is the premier meeting in rheumatology. With more than 450 sessions and thousands of abstracts, it offers a superior combination of basic science, clinical science, tech-med courses, career enhancement education and interactive discussions on improving patient care. For more information about the meeting, visit https://www.rheumatology.org/Annual-Meeting, or join the conversation on Twitter by following the official #ACR19 hashtag.
About the American College of Rheumatology
The American College of Rheumatology (ACR) is an international medical society representing over 8,500 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.
Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Background/Purpose: Billions of public dollars are spent each year on biologic disease-modifying anti-rheumatic drugs (bDMARDs), but the drivers of bDMARD spending and per-patient cost increases are unclear. We characterized changes in total spending and unit-prices for bDMARDs in Medicare and Medicaid and quantified the major sources of spending increases for public programs and beneficiaries.
Methods: Data Source and Measures: We accessed Medicare Parts B & D and Medicaid drug spending data for years 2012-2016. These contained aggregated prescription claims for all beneficiaries enrolled in Medicare Parts B (fee-for-service) or Part D (stand-alone or Medicare Advantage plans) or Medicaid. All bDMARDs with FDA approval for ≥ 1 rheumatic disease through Dec. 2014 were included. For each bDMARD and calendar-year we extracted total annual spending, and number of recipients, claims, and doses dispensed, and calculated drug unit-price (average cost/dose).
Statistical Analysis: We calculated five-year changes in total spending and unit-prices for each bDMARD and in-aggregate, after adjusting for general inflation to 2016 dollars. We then performed standard decomposition analyses to isolate the contributions of four sources of spending growth (drug prices, uptake [number of recipients], treatment intensity [mean # of doses per-claim], and annual # of claims per-recipient) for each bDMARD. We conducted our analysis including statutory Medicaid rebates (as these decrease public spending), and both excluding and including Medicare rebates (as these are paid by manufacturers to Pharmacy Benefit Managers and Part D plans). We used time-varying rebates reported by the Congressional Budget Office.
Results: From 2012-2016, annual spending on the 11 included bDMARDs by US public programs and beneficiaries nearly doubled (from $5.3 to $10.3 billion); drug prices increased by a mean of 52% in Part D and just 20% in Part B (Table). Controlling for general inflation, unit-price increases alone accounted for 56% ($1.7 billion) of the five-year, $3.0 billion spending increase within Part D (Figure); increased uptake accounted for 37% ($1.1 billion). After accounting for time-varying rebates, price hikes were still responsible for 53% ($1.4 billion) of the Part D spending increase. Adalimumab and etanercept, two of the oldest bDMARDs, were prescribed to the largest numbers of Part D beneficiaries and had the biggest unit-price increases: 84% and 88%, respectively. Medicaid spending and price trends were similar to Part D (Figure).
Majority of spending growth for the oldest Part B drugs (rituximab, abatacept, and infliximab) was from price increases (72-88%), while for the five newer drugs (golimumab, ustekinumab, tocilizumab, certolizumab, and belimumab), number of recipients was the main driver (63-81% of spending growth).
Conclusions: Post-market drug-price changes alone accounted for the majority of recent bDMARD spending growth, and manufacturers’ rebates had little impact on these findings. Beyond rebates, policy interventions that target price increases, particularly under Part D plans, may help mitigate public-payer drug spending and out-of-pocket costs for the elderly and disabled beneficiaries who rely on bDMARDs.